Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuechen ZhangYZYanru ZhangMLMenghan Liu

Discussion

Loading...

Member takes

Overview

Phase 1 trial shows a 100% overall response rate for combined therapy in relapsed/refractory multiple myeloma, indicating improved outcomes and safety profile.

Key Points

  • A 100% overall response rate was observed among patients with relapsed/refractory multiple myeloma at the recommended phase 2 regimen.
  • Adverse events included cytokine release syndrome in 83.3% of patients, with no grade 3 or 4 cases reported.
  • Phase 1 trial analyzed essential safety and efficacy metrics for the aponermin and bispecific antibody combinations.
  • These findings support further evaluation of combined therapies targeting multiple myeloma with high-risk features.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08fhttps://doi.org/10.1182/blood-2025-7576
View Full Paper
Ask AI
Bookmark
Share